compound introduction
Information PK150 is an analogue of Sorafenib and shows oral bioavailability and antibacterial activity against several pathogenic strains at submicromolar concentrations. PK150 is an inhibitor of Gram-positive Methicillin-sensitive S. aureus (MSSA), Methicillin-resistant S. aureus (MRSA) and Vancomycin intermediate S. aureus (VISA) with MIC of 0.3 µM, 0.3-1 µM and 0.3 µM, respectively.
